Successful Treatment of a Mesangial Proliferative Glomerulonephritis with Interstitial Nephritis Associated with Castleman's Disease by an Anti-interleukin-6 Receptor Antibody (Tocilizumab)
-
- Otani Naoko
- Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
-
- Morishita Yoshiyuki
- Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
-
- Oh Iekuni
- Division of Hematology, Department of Internal Medicine, Jichi Medical University, Japan
-
- Saito Osamu
- Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
-
- Takemoto Fumi
- Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
-
- Muto Shigeaki
- Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
-
- Kusano Eiji
- Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
この論文をさがす
説明
We report a case of mesangial proliferative glomerulonephritis with interstitial nephritis associated with multicentric Castleman's disease (MCD) successfully treated with an anti-interleukin-6 receptor antibody (tocilizumab). This mesangial proliferative glomerulonephritis with interstitial nephritis was resistant to methylprednisolone treatment; however, it was markedly improved with tocilizumab, which was administered intravenously at a dose of 8 mg/kg every 2 weeks. These results suggest that tocilizumab is effective for the treatment of mesangial proliferative glomerulonephritis with interstitial nephritis associated with MCD.<br>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 51 (11), 1375-1378, 2012
一般社団法人 日本内科学会
